XNK Therapeutics to present at Redeye Regenerative Medicine/Cell Therapy event
XNK Therapeutics AB (“XNK”) today announced that Johan Liwing, CEO, will present the company at the Redeye Regenerative Medicine/Cell Therapy event on February 14.
XNK Therapeutics AB (“XNK”) today announced that Johan Liwing, CEO, will present the company at the Redeye Regenerative Medicine/Cell Therapy event on February 14.
XNK Therapeutics AB (“XNK”) today announced that evencaleucel has received a scientific recommendation from the Committee for Advanced Therapies (CAT) of the European Medicines Agency (EMA). This recommendation classifies evencaleucel as a Somatic Cell Therapy Medicinal Product (sCTMP) within the category of Advanced Therapy Medicinal Products (ATMPs).